| Overview |
| bs-5820R-Cy5 |
| USP28 Polyclonal Antibody, Cy5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse |
| Human, Rat |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human USP28 |
| 101-200/1077 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 57646 |
| Nucleus |
| Deubiquitinating enzyme 28; KIAA1515; Ubiquitin carboxyl terminal hydrolase 28; Ubiquitin carboxyl-terminal hydrolase 28; Ubiquitin specic peptidase 28; Ubiquitin specic processing protease 28; Ubiquitin specic protease 28; Ubiquitin thioesterase 28; Ubiquitin thiolesterase 28; Ubiquitin-specic-processing protease 28; UBP28_HUMAN; USP 28; USP28; USP28 protein; USP-28. |
| Deubiquitinase involved in DNA damage response checkpoint and MYC proto-oncogene stability. Involved in DNA damage induced apoptosis by specifically deubiquitinating proteins of the DNA damage pathway such as CLSPN. Also involved in G2 DNA damage checkpoint, by deubiquitinating CLSPN, and preventing its degradation by the anaphase promoting complex/cyclosome (APC/C). In contrast, it does not deubiquitinate PLK1. Specifically deubiquitinates MYC in the nucleoplasm, leading to prevent MYC degradation by the proteasome: acts by specifically interacting with isoform 1 of FBXW7 (FBW7alpha) in the nucleoplasm and counteracting ubiquitination of MYC by the SCF(FBW7) complex. In contrast, it does not interact with isoform 4 of FBXW7 (FBW7gamma) in the nucleolus, allowing MYC degradation and explaining the selective MYC degradation in the nucleolus. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz